These findings suggest that modulators of CB2 have subtle pharmacological complexities, and understanding these differences may provide insight into developing better treatments for brain disorders such as schizophrenia, pain, and Alzheimer’s disease. The gene discussed is CNR2; the disease is schizophrenia.